Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 11, 2025Frontiers in ImmunologyOpen Access

Comparative short-term efficacy of Janus kinase 1 inhibitors and anti-interleukin-13 antibodies in atopic dermatitis: a retrospective cohort analysis based on real-world data

View Full Paper
Ask AI
Bookmark
Share

Authors

ESEmi SatoNONaoko ObonaiMIMayuko Iwata

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows JAK1 inhibitors improved pruritus more than IL-13 antibodies, highlighting biomarker correlations.

Key Points

  • JAK1 inhibitors demonstrated superior antipruritic effects compared to anti-interleukin-13 antibodies at 3 months.
  • Odds of achieving a significant reduction in pruritus score (PP-NRS) were 9.36 for JAK1 inhibitors, indicating strong efficacy.
  • This retrospective cohort analysis involved 75 patients with moderate-to-severe atopic dermatitis treated with either JAK1 inhibitors or IL-13 antibodies.
  • Eosinophil count reduction served as a key biomarker reflecting the effectiveness of JAK1 inhibitors in this patient cohort.

Cite This Study

Sato et al. (2025) studied this question.

synapsesocial.com/papers/68af296ecf1dd9ea359e2b37https://doi.org/10.3389/fimmu.2025.1639932
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Upadacitinib Leads in Efficacy: A Bayesian Network Meta‐Analysis of Four <scp>JAK</scp> Inhibitors in Moderate‐To‐Severe Atopic Dermatitis2026
  2. 2Clinical and inflammatory determinants of successful abrocitinib dose reduction in atopic dermatitis: a real-world cohort study with implications for treatment optimization2026
  3. 3The Use of JAK Inhibitors in AD Affecting Difficult-to-Treat Areas: Lessons from Real-Life2026
  4. 4Characteristics of Adult Patients With Atopic Dermatitis Initiating Biologics and Janus Kinase Inhibitors in the CorEvitas Atopic Dermatitis Registry2025
  5. 5[Progress in the application of JAK inhibitors in atopic dermatitis].2025